Securian Asset Management Inc. Sells 427 Shares of Moderna, Inc. (NASDAQ:MRNA)

Securian Asset Management Inc. decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,200 shares of the company’s stock after selling 427 shares during the quarter. Securian Asset Management Inc.’s holdings in Moderna were worth $757,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Banco Santander S.A. bought a new stake in Moderna during the 3rd quarter valued at about $3,550,000. John G Ullman & Associates Inc. increased its position in Moderna by 341.3% during the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after purchasing an additional 38,400 shares during the period. abrdn plc increased its position in Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares during the period. Y Intercept Hong Kong Ltd increased its position in Moderna by 30.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after purchasing an additional 23,881 shares during the period. Finally, Spire Wealth Management increased its position in Moderna by 2,150.4% during the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after purchasing an additional 22,192 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 0.9 %

Shares of NASDAQ MRNA opened at $34.62 on Friday. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company has a 50 day simple moving average of $35.94 and a two-hundred day simple moving average of $47.37. The stock has a market cap of $13.36 billion, a price-to-earnings ratio of -3.73 and a beta of 1.86.

Analyst Ratings Changes

A number of research analysts have commented on MRNA shares. Morgan Stanley cut their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Berenberg Bank raised their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna has an average rating of “Hold” and an average price target of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.